UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Revenues [Abstract]
Total revenues	$ 0			$ 14,229				$ 22,334	$ 48,220
Operating expenses:
Cost of products	0			2,823				5,742	9,711
Research and development expenses	5,569			7,539				15,156	25,160
Selling, general and administrative expenses	8,423			5,316				23,431	22,520
Intangible asset amortization	0			205				406	610
Changes in fair value of contingent consideration	(69)			627				3,327	2,384
Gain on sale of Hospital Products	0			0			$ (45,760)	(45,760)	0
Restructuring (income) costs	(226)			1,866				(43)	4,600
Total operating expense	13,697			18,376				2,259	64,985
Operating (loss) income	(13,697)			(4,147)				20,075	(16,765)
Investment and other income (expense), net	213			781				(906)	2,548
Interest expense	(3,259)			(3,125)				(9,686)	(9,293)
Loss on deconsolidation of subsidiary	0			0				0	(2,840)
Other expense - changes in fair value of contingent consideration payable	0			(139)				(435)	(496)
(Loss) income before income taxes	(16,743)			(6,630)				9,048	(26,846)
Income tax (benefit) provision	(5,040)			2,234				(9,258)	3,641
Net (loss) income	$ (11,703)	$ 30,874	$ (865)	$ (8,864)	$ (8,605)	$ (13,018)		$ 18,306	$ (30,487)
Net income (loss) per share - basic (in dollars per share)	$ (0.20)			$ (0.24)				$ 0.36	$ (0.82)
Net income (loss) per share - diluted (in dollars per share)	$ (0.20)			$ (0.24)				$ 0.35	$ (0.82)
Weighted average number of shares outstanding - basic (in shares)	58,213			37,436				51,206	37,382
Weighted average number of shares outstanding - diluted (in shares)	58,213			37,436				52,849	37,382